FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab

FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab

IntroductionTargeting costimulatory receptors of the tumor necrosis factor receptor (TNFR) superfamily with agonistic antibodies is a promising approach in cancer immuno therapy. It is known that their efficacy strongly depends on FcγR cross-linking.MethodsIn this study, we made use of a Jurkat-base...

Full description

Bibliographic Details
Main Authors: Judith Leitner, Ricarda Egerer, Petra Waidhofer-Söllner, Katharina Grabmeier-Pfistershammer, Peter Steinberger
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
human T cell costimulation
41BB
CD137
CD27
agonistic antibodies
Urelumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1208631/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1208631/full

Similar Items